These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 14781902)

  • 1. [Myographic study on the effects of diethylamino-ethyl-N-thiodiphenylamine chlorhydrate on the hypertonia of Parkinson's disease].
    DELMAS-MARSALET P; FAURE J; ARNE L
    Sem Hop; 1950 Sep; 26(65):3443-54. PubMed ID: 14781902
    [No Abstract]   [Full Text] [Related]  

  • 2. [Mechanism of action of diethylamino-ethyl-N-dibenzo-parathiazine on extrapyramidal hypertonia].
    DELMAS-MARSALET P; FAURE J; ARNE L
    C R Seances Soc Biol Fil; 1950 Sep; 144(17-18):1163-5. PubMed ID: 14801876
    [No Abstract]   [Full Text] [Related]  

  • 3. Agranulocytosis following treatment of Parkinson's syndrome with "diparcol" (diethyl-amino-ethylphenothiazine): a report of two cases.
    PILCHER RB
    Med J Aust; 1950 Aug; 2(8):295-9. PubMed ID: 14779563
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of the tremor-rigidity syndrome (Parkinson's syndrome) with "diparcol".
    REID WL
    Med J Aust; 1950 Apr; 1(14):465-7. PubMed ID: 15416371
    [No Abstract]   [Full Text] [Related]  

  • 5. [Pharmacological properties of (diethylamino-28 propyl-18)-N phenothiazine. Pharmacological study of a new active compound in Parkinson disease].
    FOURNEL J
    J Physiol (Paris); 1950; 42(4):877-89. PubMed ID: 14825173
    [No Abstract]   [Full Text] [Related]  

  • 6. [Antagonism of dibenzothiazine derivatives (diparcol, parsidol, phenergan) towards the central effects of nicotine; correspondence with clinical experimentation in Parkinson's disease].
    BOVET D; DUREL P; LONGO V
    C R Seances Soc Biol Fil; 1950 Apr; 144(7-8):514-7. PubMed ID: 14773059
    [No Abstract]   [Full Text] [Related]  

  • 7. [Trial treatment of Parkinson's disease].
    LEBLOND S; PICHETTE R
    Laval Med; 1951 Feb; 16(2):156-64. PubMed ID: 14825940
    [No Abstract]   [Full Text] [Related]  

  • 8. [Treatment of paralysis agitans with some new preparations: parpanit, diparcol, and phenergan].
    WINTHER K
    Ugeskr Laeger; 1950 May; 112(21):754-8. PubMed ID: 15443113
    [No Abstract]   [Full Text] [Related]  

  • 9. [Myographic and clinical observations on two new antihistaminics used in the treatment of parkinsonism].
    STEGER R; HUFSCHMIDT HJ
    Dtsch Z Nervenheilkd; 1958; 178(4):413-30. PubMed ID: 13609390
    [No Abstract]   [Full Text] [Related]  

  • 10. [Mode of action of a synthetic derivative of phenothiazine having a therapeutic effect in Parkinson's disease].
    ALTAMIRANO M; UIBERALL E; SOLARI G
    Gaz Med Fr; 1951 Feb; 58(4):221-5. PubMed ID: 14823241
    [No Abstract]   [Full Text] [Related]  

  • 11. PHARMACOLOGICAL PARKINSON'S SYNDROME.
    PITHA V; POLAK O
    Act Nerv Super (Praha); 1964; 6():88. PubMed ID: 14140612
    [No Abstract]   [Full Text] [Related]  

  • 12. [Results of use of diparcol in the treatment of parkinsonian syndromes].
    MELARAGNO FILHO R
    Rev Paul Med; 1950 Jul; 37(1):47-52. PubMed ID: 15441523
    [No Abstract]   [Full Text] [Related]  

  • 13. Diparcol therapy for parkinsonism.
    PALMER H; BLACK H
    N Z Med J; 1949 Oct; 48(267):487-90. PubMed ID: 15395674
    [No Abstract]   [Full Text] [Related]  

  • 14. [First results of a new treatment of Parkinson's disease and of parkinsonism; therapeutic effect of 3-phenyl-3-(beta-diethylamino-ethyl)-2, 6-dioxo piperidine alone and with reserpine and ritalin; preliminary note].
    GIANNIOTTI G; GIBERTI F; SPIZZIRRI S
    Gazz Med Ital; 1956 Mar; 115(3):71-4. PubMed ID: 13344883
    [No Abstract]   [Full Text] [Related]  

  • 15. Phenothiazines: curative or causative in regard to parkinsonism?
    COTZIAS GC; BORG DC; HUGHES ER; BERTINCHAMPS A; PAPAVASILIOU PS
    Rev Can Biol; 1961 Jun; 20():289-94. PubMed ID: 13881684
    [No Abstract]   [Full Text] [Related]  

  • 16. [Modern drugs in the treatment of parkinsonism and similar diseases].
    UIBERALL E; JORDAN J
    Rev Med Chil; 1950 Jul; 78(7):451-6. PubMed ID: 15441476
    [No Abstract]   [Full Text] [Related]  

  • 17. [A new drug for Parkinson's syndromes symptoms, hydrochloride of [(diethylamino-2'-methyl-2 ') - ethyl]' N-dibenzoparathiazine.].
    Sigwald J
    Presse Med (1893); 1949 Sep; 57(59):819. PubMed ID: 18142002
    [No Abstract]   [Full Text] [Related]  

  • 18. Diparcol in the treatment of Parkinsonism.
    BARRADA Y; HASSAN AH; GUINENA Y; EL NABY SA; TAHER Y
    J Egypt Med Assoc; 1952; 35(8):503-15. PubMed ID: 13000785
    [No Abstract]   [Full Text] [Related]  

  • 19. C9ORF72 intermediate repeat expansion in patients affected by atypical parkinsonian syndromes or Parkinson's disease complicated by psychosis or dementia in a Sardinian population.
    Cannas A; Solla P; Borghero G; Floris GL; Chio A; Mascia MM; Modugno N; Muroni A; Orofino G; Di Stefano F; Calvo A; Moglia C; Restagno G; Meloni M; Farris R; Ciaccio D; Puddu R; Vacca MI; Melis R; Murru MR; Tranquilli S; Corongiu D; Rolesu M; Cuccu S; Marrosu MG; Marrosu F
    J Neurol; 2015 Nov; 262(11):2498-503. PubMed ID: 26275564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lysivane in the treatment of Parkinsonism.
    GILLHESPY RO
    Edinb Med J; 1953 Aug; 60(8):365-70. PubMed ID: 13083580
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.